Lumipulse® G pTau 217/β-Amyloid 1-42 Ratio (Plasma)
Alzheimer's Disease (Amyloid Pathology)
CommercialFDA Cleared, CE Marked
Key Facts
Indication
Alzheimer's Disease (Amyloid Pathology)
Phase
Commercial
Status
FDA Cleared, CE Marked
Company
About fujirebio-diagnostics
Fujirebio Diagnostics is an R&D-driven innovator and global provider of in vitro diagnostic solutions, with a mission to create new value in healthcare. Its core achievement is pioneering blood-based biomarkers for Alzheimer's disease, including the first FDA-cleared blood test for amyloid pathology. The company's strategy leverages its proprietary Lumipulse® G platform for internal assay development while operating a synergistic CDMO business, reinvesting partnership revenues to fuel a robust pipeline in neurology, oncology, and infectious diseases.
View full company profileTherapeutic Areas
Other Alzheimer's Disease (Amyloid Pathology) Drugs
| Drug | Company | Phase |
|---|---|---|
| Lumipulse® G β-Amyloid 1-42/1-40 Ratio (Plasma) | fujirebio-diagnostics | Commercial |